In vivo CAR-T therapy transforms T cells directly within the body, making treatment faster, simpler, and more accessible, with the potential for repeat dosing and targeting solid tumors. Antibodies guide CAR constructs to tumor-specific antigens, enabling precise T cell activation and proliferation, while supporting multispecific designs that enhance efficacy and reduce off-target effects.

Join ProBio’s webinar to learn how to discover and develop antibodies for in vivo CAR-T applications.